Fenix seems to think the pathway to approval for cancer will be easier than BPH, but I am greedy and want them both
Anyone fed up and selling on the next rip? ...not me
Institution ownership has gone up. Blackrock has over a million shares now.
Why no movement? They're getting more info out, releasing ERs on time and attending conferences?
"Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce recent completion of private placements with proceeds totaling US $3.0 million. There were no warrants or fees associated with the transactions. The placements were with long-term shareholders of the Company, and will be used for general corporate purposes."
Is there anyway of knowing how many shares were sold for the $3 million. Curious to know at what share price. An SEC filing doesn't need to occur here??
Wow less than 5K volume 2 hours into trading!
Yippee, that are presenting in September. That's a start
Question??? The AUA Presentation is being given on Saturday morning 7:00am-8:00am. Why so early? Who's going to be up????
Aqua will be happy. They filed their Q2 report
this stock is #$%$ up
a Yahoo! Local User
This article talks about EU average approval timelines. We could be looking at almost 400 days from submission.
Speed up drug approvals at FDA? It's already faster than Europe's drug agency
Amidst Trump's calls for faster drug approvals, new research finds that FDA's process is more efficient than Europe's
Markets were expecting more than just a "Symposium"
Robinson buys 15,000 more shares between 7/28-8/1. Wonder if this has any impact on the timing of news release?
Aqua, why so quiet?
So what is the deal on the private placement of $3 million? Is that good?
Wow That was fast!
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Director James George Robinson purchased 11,500 shares of the business’s stock in a transaction that occurred on Friday, July 7th. The stock was bought at an average cost of $4.00 per share, with a total value of $46,000.00. Following the acquisition, the director now owns 3,046,550 shares of the company’s stock, valued at approximately $12,186,200. The purchase was disclosed in a document filed with the Securities & Exchange Commission,
New Insider Filing on Director JAMES GEORGE ROBINSON: #insideri.com/1651844_000165…